ANIPANI Pharmaceuticals, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−5% vs 200-day) and heavily shorted (+12% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −5% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ANIP is trading
ANI Pharmaceuticals, Inc. is −24% over the past year while the S&P 500 is +18%: 42 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −5.5%
vs 200-day average · below trend, but not far
- RSI (14)
- 31
RSI (14) · neutral
- Below its 52-week high
- 23%
Below its 52-week high
Details›
- Last close2026-10-09
- $73.92
- 1 monthS&P 500 +2.7%
- +3.5%
- 1 yearS&P 500 +18%
- −24%
- 5 yearsS&P 500 +88%
- +169%
- vs 50-day average$74.70
- −1.1%
- 52-week high
- $95.93
- 52-week low
- $70.16
- Annualised volatility
- 35%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- −$5.9M
| Year | Return |
|---|---|
| 2026 (year to date) | −6.4% |
| 2025 | +43% |
| 2024 | +0.25% |
| 2023 | +37% |
| 2022 | −13% |
| 2021 | +59% |
| 2020 | −53% |
| 2019 | +37% |
| 2018 | −30% |
| 2017 | +6.3% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 7 of 10 | +3.2% |
| Feb | 10 | 4 of 10 | −0.18% |
| Mar | 10 | 5 of 10 | −2.5% |
| Apr | 10 | 6 of 10 | +0.67% |
| May | 10 | 4 of 10 | −3.1% |
| Jun | 10 | 8 of 10 | +6.9% |
| Jul | 11 | 6 of 11 | +1.3% |
| Aug | 11 | 4 of 11 | +2.0% |
| Sep | 11 | 4 of 11 | −0.45% |
| Oct | 11 | 6 of 11 | +1.9% |
| Nov | 10 | 5 of 10 | +2.4% |
| Dec | 10 | 4 of 10 | −1.9% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #9 of 41 by RyuScore